REFERENCES
- Smith L E. Pathogenesis of retinopathy of prematurity. Acta Paediatr Suppl. 2002; 91: 26–28, [PUBMED], [INFOTRIEVE], [CSA]
- Connolly S E, Hores T A, Smith L E, D'Amore P A. Characterization of vascular development in the mouse retina. Microvasc Res. 1988; 36: 275–290, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Fruttiger M. Development of the mouse retinal vasculature: angiogenesis versus vasculogenesis. Invest Ophthalmol Vis Sci. 2002; 43: 522–527, [PUBMED], [INFOTRIEVE], [CSA]
- Yancopoulos G D, Davis S, Gale N W, Rudge J S, Wiegand S J, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000; 407: 242–248, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Carmeliet P, Jain R K. Angiogenesis in cancer and other diseases. Nature. 2000; 407: 249–257, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003; 9: 653–660, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Stamenocovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 2000; 10: 415–433, [CROSSREF], [CSA]
- Ravanti L, Kahari V M. Matrix metalloproteinases in wound repair. Int J Mol Med 2000; 6: 391–407, [PUBMED], [INFOTRIEVE], [CSA]
- Zhou Z, Apte S S, Soininen R, Cao R, Baaklini G Y, Rauser R W, Wang J, Cao Y, Tryggvason K. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci USA 2000; 97: 4052–4057, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sethi C S, Bailey T A, Luthert P J, Chong N HV. Matrix metalloproteinase biology applied to vitreoretinal disorders. Br J Ophthalmol 2000; 84: 654–666, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998; 58: 1048–1051, [PUBMED], [INFOTRIEVE]
- Bergers G, Brekken R, McMahon G, Vu T H, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737–744, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Berglin L, Sarman S, van der Ploeg I, Steen B, Ming Y, Itohara S, Seregard S, Kvanta A. Reduced choroidal neovascular membrane formation in matrix metalloproteinase-2-deficient mice. Invest Ophthalmol Vis Sci. 2003; 44: 403–408, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lambert V, Wielockx B, Munaut C, Galopin C, Jost M, Itoh T, Werb Z, Baker A, Libert C, Krell H W, et al. MMP-2 and MMP-9 synergize in promoting choroidal neovascularization. FASEB J. 2003; 17: 2290–2292, [PUBMED], [INFOTRIEVE]
- Kohri T, Moriwaki M, Nakajima M, Tabuchi H, Shiraki K. Reduction of experimental laser-induced choroidal neovascularization by orally administered BPHA, a selective metalloproteinase inhibitor. Graefes Arch Clin Exp Ophthalmol 2003; 241: 943–952, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Steen B, Sejersen S, Berglin L, Seregard S, Kvanta A. Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1998; 39: 2194–2200, [PUBMED], [INFOTRIEVE], [CSA]
- Kvanta A, Shen W Y, Sarman S, Seregard S, Steen B, Rakoczy E. Matrix metalloproteinase (MMP) expression in experimental choroidal neovascularization. Curr Eye Res 2000; 21: 684–690, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Das A, McGuire P G, Eriqat C, Ober R R, DeJuan E, Jr, Williams G A, McLamore A, Biswas J, Johnson D W. Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci 1999; 40: 809–813, [PUBMED], [INFOTRIEVE], [CSA]
- Das A, McLamore A, Song W, McGuire P G. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol 1999; 117: 498–503, [PUBMED], [INFOTRIEVE], [CSA]
- Itoh T, Ikeda T, Gomi H, Nakao S, Suzuki T, Itohara S. Unaltered secretion of beta-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J Biol Chem 1997; 272: 22389–22392, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Smith L E, Wesolowski E, McLellan A, Kostyk S K, D'Amato R, Sullivan R, D'Amore P A. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994; 35: 101–111, [PUBMED], [INFOTRIEVE], [CSA]
- Okada A, Tomasetto C, Lutz Y, Bellocq J P, Rio M C, Basset P. Expression of matrix metalloproteinases during rat skin wound healing: evidence that membrane type-1 matrix metalloproteinase is a stromal activator of pro-gelatinase A. J Cell Biol 1997; 137: 67–77, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kuzuya M, Kanda S, Sasaki T, Tamaya-Mori N, Cheng X W, Itoh T, Itohara S, Iguchi A. Deficiency of gelatinase A suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia. Circulation 2003; 108: 1375–1381, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kato T, Kure T, Chang J H, Gabison E E, Itoh T, Itohara S, Azar D T. Diminished corneal angiogenesis in gelatinase A-deficient mice. FEBS Lett 2001; 508: 187–190, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wang Y S, Friedrichs U, Eichler W, Hoffmann S, Wiedemann P. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol 2002; 240: 42–48, [PUBMED], [INFOTRIEVE], [CSA]
- Ohno-Matsui K, Uetama T, Yoshida T, Hayano M, Itoh T, Morita I, Mochizuki M. Reduced retinal angiogenesis in MMP-2-deficient mice. Invest Ophthalmol Vis Sci. 2003; 44: 5370–5537, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Majka S, McGuire P, Colombo S, Das A. The balance between proteinases and inhibitors in a murine model of proliferative retinopathy. Invest Ophthalmol Vis Sci 2001; 42: 210–215, [PUBMED], [INFOTRIEVE], [CSA]
- Samolov B, Steen B, Seregard S, van der Ploeg I, Montan P, Kvanta A. Delayed inflammation-associated corneal neovascularization in MMP-2-deficient mice. Exp Eye Res. 2005; 80: 159–166, [PUBMED], [INFOTRIEVE], [CROSSREF]
- O'Reilly M S, Wiederschain D, Stetler-Stevenson W G, Folkman J, Moses M A. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 1999; 274: 29568–29571, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Drixler T A, Rinkes I H, Ritchie E D, Treffers F W, van Vroonhoven T J, Gebbink M F, Voest E E. Angiostatin inhibits pathological but not physiological retinal angiogenesis. Invest Ophthalmol Vis Sci 2001; 42: 3325–3330, [PUBMED], [INFOTRIEVE], [CSA]
- Raisler B J, Berns K I, Grant M B, Beliaev D, Hauswirth W W. Adeno-associated virus type-2 expression of pigmented epithelium-derived factor or Kringles 1-3 of angiostatin reduce retinal neovascularization. Proc Natl Acad Sci USA 2002; 99: 8909–8914, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Garcia C, Bartsch D U, Rivero M E, Hagedorn M, McDermott C D, Bergeron-Lynn G, Cheng L, Appelt K, Freeman W R. Efficacy of Prinomastat® (AG3340), a matrix metalloprotease inhibitor, in treatment of retinal neovascularization. Curr Eye Res 2002; 24: 33–38, [PUBMED], [INFOTRIEVE], [CROSSREF]